Page 27 - Multiple System Atrophy News Today

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

Highlights: MELBOURNE, Australia, Jan. 27, 2022 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2021 (Q2 FY22). The Company's cash position on...

Highlights: NZ’s regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications...

Alterity Therapeutics Ltd. (ATHE) stock rallied in the after hours following the announcement of its upcoming presentation.

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course...

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course...

Initiation of Phase 2 Clinical Trial Expected in CY Q1 2022 MELBOURNE, Australia, Dec. 14, 2021 /PRNewswire/ — Alterity Therapeutics (ASX:...

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

Supporter information for QPR v Stoke City at Kiyan Prince Foundation Stadium.

Dawn Collins says she can finally get rid of the thousands of pages of documents she amassed during her long battle against Veterans Affairs. It’s a fight that began when her husband, a naval veteran, was diagnosed with a rare neurodegenerative disease in 2008.